Patents by Inventor Francis J Carr

Francis J Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040254106
    Abstract: The invention in particular relates to the modification of human factor IX to result in factor IX proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo. The invention relates, furthermore, to T-cell epitope sequences deriving from human factor IX, which are immunogenic.
    Type: Application
    Filed: March 4, 2004
    Publication date: December 16, 2004
    Inventors: Francis J. Carr, Graham Carter
  • Publication number: 20040213791
    Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.
    Type: Application
    Filed: May 30, 2002
    Publication date: October 28, 2004
    Inventors: Neil Bander, Francis J. Carr, Anita Hamilton
  • Publication number: 20040185038
    Abstract: This invention relates to the fields of immunology and protein therapeutics. The therapeutic proteins are polypeptides to be administered especially to humans. The polypeptides are modified whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention therefor provides methods for the development of therapeutic polypeptides that are less immunogenic than any non-modified counterpart when used in vivo. The modifications used according to this invention relate, for example, to the introduction of protease cleavage sites, attachment of different molecules or insertion of non-natural amino acids.
    Type: Application
    Filed: January 8, 2004
    Publication date: September 23, 2004
    Inventors: Francis J Carr, Graham Carter, Koen Hellendoorn
  • Publication number: 20040180386
    Abstract: This invention relates to a novel approach for identification of T-cell epitopes, that give rise to an immune reaction in a living host. By means of this novel method biological compounds can be generated which have a no or at least a reduced immunogenicity when exposed to the immune system of a given species and compared with the relevant non-modified entity. Thus the invention relates also to novel biological molecules, especially proteins and antibodies, obtained by the method according to the invention.
    Type: Application
    Filed: August 19, 2003
    Publication date: September 16, 2004
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams, Anita Hamilton
  • Publication number: 20040121443
    Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of protamine to result in protamine proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
    Type: Application
    Filed: February 9, 2004
    Publication date: June 24, 2004
    Inventors: Francis J. Carr, Graham Carter
  • Publication number: 20040120958
    Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.
    Type: Application
    Filed: May 30, 2003
    Publication date: June 24, 2004
    Inventors: Neil H. Bander, Francis J. Carr, Anita Hamilton
  • Publication number: 20040096442
    Abstract: The present invention relates to antibodies which are directed to the EGF receptor (HER 1) to be administered especially to humans and in particular for therapeutic use in tumors. The antibodies are modified whereby the modification results in a reduced propensity for the antibody to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of anti-EGFR antibody 425 in its different forms and fragments thereof to result in Mab 425 variants that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
    Type: Application
    Filed: August 19, 2003
    Publication date: May 20, 2004
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams, Anita Hamilton
  • Publication number: 20040087503
    Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human ciliary neutrophic factor (CNTF) to result in CNTF proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
    Type: Application
    Filed: September 2, 2003
    Publication date: May 6, 2004
    Inventors: Francis J. Carr, Graham Carter
  • Publication number: 20040082039
    Abstract: The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fe portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules.
    Type: Application
    Filed: August 19, 2003
    Publication date: April 29, 2004
    Inventors: Stephen Gillies, Francis J Carr, Jones Tim, Graham Carter, Anita Hamilton, Stephen Williams, Marian Hanlon, John P Watkins, Matthew Baker, Jeffrey C Way
  • Publication number: 20040076991
    Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of interleukin-1 receptor antagonist (IL-1RA) to result in IL-1RA proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 22, 2004
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams
  • Publication number: 20040072219
    Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human obesity protein (leptin) to result in leptin proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 15, 2004
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams, Anita Hamilton
  • Publication number: 20040072291
    Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human brain-derived neutrophic factor (BDNF) to result in BDNF proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 15, 2004
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams
  • Publication number: 20040071688
    Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human thrombopoietin (TPO) to result in TPO proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used <i>in vivo<i/>.
    Type: Application
    Filed: August 26, 2003
    Publication date: April 15, 2004
    Inventors: Francis J. Carr, Graham Carter
  • Publication number: 20040062749
    Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of granulocyte colony stimulating factor (G-CSF) to result in granulocyte colony stimulating factor (G-CSF) proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 1, 2004
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams
  • Publication number: 20040063634
    Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of keratinocyte growth factor (KGF) to result in keratinocyte growth factor (KGF) proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 1, 2004
    Inventors: Francis J. Carr, Carter Graham, Tim Jones, Stephen Williams
  • Publication number: 20040063917
    Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The inention in particular relates to the modification of erythropoietin (EPO) to result in erythropoietin proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 1, 2004
    Inventors: Francis J. Carr, Carter Graham, Tim Jones, Stephen Williams
  • Publication number: 20030171290
    Abstract: The present invention relates to methods to determine peptides presented on the surface of mammalian cells following addition to the cells of a protein. The present invention also relates to diagnostic tests based on the determination of such peptides or modified molecules resulting from determination of such peptides, such as pharmaceutical entities preferably having specific biological activity and reduced or enhanced immunogenicity when compared with the corresponding non-modified molecules. The methods according to this invention are preferably established with tools using mass spectroscopy (MS).
    Type: Application
    Filed: January 31, 2003
    Publication date: September 11, 2003
    Inventors: Francis J. Carr, Graham Carter, Koen Hellendoorn
  • Publication number: 20030124056
    Abstract: The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: June 26, 2002
    Publication date: July 3, 2003
    Inventors: Francis J. Carr, Anita A. Hamilton
  • Patent number: 6472365
    Abstract: A method of releasing an agent for example, a chemotherapeutic, under predetermined conditions by protecting the agent within a lipid structure such as a liposome, causing lipase activity to be constituted by combining two or more components, e.g., recombinant N- or C-terminal Clostridium perfringens alpha-toxin fragments, one of these components being conjugated to a targeting molecule e.g., an antibody which binds to a target such as a tumor antigen. The lipid structure is then exposed to the constituted lipase activity such as to release the agent. Also disclose are materials and kits for use in the method.
    Type: Grant
    Filed: March 16, 1998
    Date of Patent: October 29, 2002
    Assignee: Biovation Limited
    Inventors: Richard W Titball, Francis J Carr
  • Publication number: 20020035084
    Abstract: A method of releasing an agent (e.g. a chemotherapeutic) under predetermined conditions comprising the steps of protecting the agent within a lipid structure (e.g. a liposome), causing lipase activity to be constituted by combining two or more components (e.g. recombinant N- or C-terminal Clostridium perfringens alpha-toxin fragments), one of these components being conjugated to a targeting molecule (e.g. an antibody) which binds to a target (e.g. a tumour antigen) under the predetermined conditions. The lipid structure is then exposed to the constituted lipase activity such as to release the agent. Also disclosed are materials and kits for use in the method.
    Type: Application
    Filed: November 21, 2001
    Publication date: March 21, 2002
    Inventors: Richard W. Titball, Francis J. Carr